Literature DB >> 11345832

Immunoreactivity for hepatocyte paraffin 1 antibody in hepatoid adenocarcinomas of the gastrointestinal tract.

A Maitra1, L A Murakata, J Albores-Saavedra.   

Abstract

Hepatocyte paraffin 1 (Hep Par 1) is a monoclonal antibody considered almost specific for normal and neoplastic hepatocytes, that can be used on formalin-fixed paraffin-embedded tissues. Hep Par 1 reactivity has been demonstrated consistently in hepatocellular carcinomas and hepatoblastomas but only rarely in cholangiocarcinomas and metastatic tumors to the liver. Although its role as a marker of hepatocytic differentiation in primary liver tumors has been studied extensively, Hep Par 1 expression has not been explored in extrahepatic lesions, especially rare adenocarcinomas with hepatoid morphologic features. We studied 7 hepatoid adenocarcinomas of the gastrointestinal tract (6 gastric and 1 from the gallbladder) for Hep Par 1 immunoreactivity. Focal Hep Par 1 expression was seen in 6 of 7 tumors. These hepatoid adenocarcinomas also showed reactivity for alpha-fetoprotein and carcinoembryonic antigen. The presence of Hep Par 1 reactivity in extrahepatic hepatoid adenocarcinomas underscores the fact that Hep Par 1 expression is not unique to primary hepatocellular neoplasms. Adenocarcinomas with hepatoid features must be considered in the differential diagnosis of Hep Par 1-positive lesions.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11345832     DOI: 10.1309/5C2C-FP3H-GE7Q-2XJ5

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  23 in total

Review 1.  Hepatoid Adenocarcinoma of the Gallbladder : Case Report and Literature Review.

Authors:  Anastasios J Karayiannakis; Stylianos Kakolyris; Alexandra Giatromanolaki; Nikos Courcoutsakis; Helen Bolanaki; Leonidas Chelis; Efthimios Sivridis; Constantinos Simopoulos
Journal:  J Gastrointest Cancer       Date:  2012-09

2.  Hepatoid adenocarcinoma of the gallbladder with production of alpha-fetoprotein.

Authors:  Jae Hoon Lee; Kyeong Geun Lee; Seung Sam Paik; Hwon Kyum Park; Kwang Soo Lee
Journal:  J Korean Surg Soc       Date:  2011-06-09

Review 3.  [Diagnosis and differential diagnosis of hepatocellular carcinoma].

Authors:  U Drebber; H P Dienes
Journal:  Pathologe       Date:  2006-07       Impact factor: 1.011

4.  Hepatoid adenocarcinoma of the gallbladder.

Authors:  H Gakiopoulou; N Givalos; G Liapis; G Agrogiannis; E Patsouris; I Delladetsima
Journal:  Dig Dis Sci       Date:  2007-05-18       Impact factor: 3.199

5.  Hepatoid adenocarcinoma of the peritoneal cavity: Prolonged survival after debulking surgery and 5-fluorouracil, leucovorin and oxaliplatin (FOLFOX) therapy.

Authors:  Zarah Dulce F Lucas; Manasi Shah; Anshu Trivedi; Mark E Dailey
Journal:  J Gastrointest Oncol       Date:  2012-06

6.  Hepatoid adenocarcinoma of the stomach: Nine case reports and treatment outcomes.

Authors:  Cheng Xiao; Fusheng Wu; Han Jiang; Lisong Teng; Fang Song; Qiangfeng Wang; Huanxia Yang
Journal:  Oncol Lett       Date:  2015-06-29       Impact factor: 2.967

7.  Carcinoma of unknown primary origin.

Authors:  Gauri R Varadhachary
Journal:  Gastrointest Cancer Res       Date:  2007-11

8.  Cerebral metastasis from hepatoid adenocarcinoma of the stomach.

Authors:  Sheng Zhang; Mi Wang; Yi-Hui Xue; Yu-Peng Chen
Journal:  World J Gastroenterol       Date:  2007-11-21       Impact factor: 5.742

Review 9.  Current concepts in the immunohistochemical evaluation of liver tumors.

Authors:  Anne K Koehne de Gonzalez; Marcela A Salomao; Stephen M Lagana
Journal:  World J Hepatol       Date:  2015-06-08

10.  Hepatoid adenocarcinoma of the stomach with liver metastasis mimicking hepatocellular carcinoma: a case report.

Authors:  Chih-Wen Lin; Chia-Chang Hsu; Hong-Cheng Chang; Yu-Chiun Sun; Po-Lin Sun; Chuan-Yan Hsu; Daw-Shyong Perng
Journal:  Cases J       Date:  2009-08-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.